AASLD 2014 Marc Bourliere speaking at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting. Photo by Liz Highleyman, hivandhepatitis.com.CirrhosisSofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis Jürgen Rockstroh, speaking at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting. Photo by Liz Highleyman, hivandhepatitis.com.HIV/HCV co-infectionAbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people with HIV co-infection David Nelson, speaking at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting. Photo by Liz Highleyman, hivandhepatitis.com.Genotype 3Daclatasvir + sofosbuvir demonstrates good cure rate for genotype 3 hepatitis C infohep news Protease inhibitors AbbVie next-generation hepatitis C drugs look promising in early studies Liz Highleyman / 03 March 2015 AbbVie's investigational HCV protease inhibitor ABT-493 and NS5A inhibitor ABT-530 demonstrated good antiviral activity in people with genotype 1 chronic hepatitis C in a three-day monotherapy study, as well as potent and ... Eligibility for treatment One million people with hepatitis C in the US at high priority for treatment Liz Highleyman / 07 January 2015 An estimated 813,000 people with diagnosed hepatitis C in the US have undergone liver disease staging and meet the 'highest' or 'high' priority criteria for immediate treatment, according to an analysis presented ... Prognosis and disease progression Many hepatitis C patients with cirrhosis or advanced fibrosis face liver failure and liver cancer Liz Highleyman / 07 January 2015 Nearly one-third of chronic hepatitis C patients with liver cirrhosis and 12% with advanced fibrosis progressed to decompensation within five years, and 23% and 11%, respectively, died, according to a study presented ... Cirrhosis Sofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis Liz Highleyman / 07 January 2015 Difficult-to-treat hepatitis C patients with liver cirrhosis who were not cured with a prior course of first-generation HCV protease inhibitors had a sustained response rate of 96-97% when re-treated with sofosbuvir/ledipasvir with ribavirin ... Interferon-free regimens Sofosbuvir + simeprevir shows good results for hepatitis C in real-world use Liz Highleyman / 09 December 2014 Regimens containing sofosbuvir (Sovaldi) – including sofosbuvir plus simeprevir (Olysio) – work well for people with hepatitis C genotype 1 in real-world use, which to date has included some of the patients most urgently ... Treatment in liver transplanted AbbVie 3D regimen cures recurrent HCV in most liver transplant recipients without cirrhosis Liz Highleyman / 08 December 2014 AbbVie's 3D regimen (newly named Viekirax + Exviera) demonstrated a sustained virological response rate of 97% for people with HCV genotype 1 recurrence after liver transplantation who had not yet developed advanced liver fibrosis ... Treatment in liver transplanted Sofosbuvir/ledipasvir with ribavirin cures most people with hepatitis C recurrence after liver transplantation Liz Highleyman / 08 December 2014 An interferon-free regimen of sofosbuvir plus ledipasvir (Harvoni) taken with ribavirin for 12 or 24 weeks led to sustained virological response in nearly all HCV genotype 1patients with fibrosis or less-advanced liver cirrhosis, researchers ... Antiviral therapy Tenofovir continues to suppress hepatitis B virus for eight years Keith Alcorn / 05 December 2014 Most people with chronic hepatitis B who are treated with tenofovir for eight years continued to maintain viral suppression, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver ... Ns5A inhibitors Daclatasvir + sofosbuvir demonstrates good cure rate for genotype 3 hepatitis C Liz Highleyman / 04 December 2014 An all-oral combination of daclatasvir (Daklinza) plus sofosbuvir (Sovaldi), taken for 12 weeks, produced sustained virological response rates of 90% for previously untreated patients and 86% for prior non-responders with hepatitis C virus ... Treatment for people living with HIV and HCV AbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people with HIV co-infection Liz Highleyman / 03 December 2014 AbbVie's 3D regimen (paritaprevir/ombitasvir/ritonavir plus dasabuvir) with ribavirin for 12 weeks and Gilead Science's sofosbuvir (Sovaldi) plus ribavirin for 24 weeks both produced good sustained virological response rates for most people with ... View more > Editors' picks from other sources Finance, funding & health economics The 2014 Liver Meeting – Report on Viral Hepatitis Coverage at the American Association for the Study of Liver Diseases (AASLD) Meeting US CDC / 19 January 2015 Ns5A inhibitors Two studies show promise for 8-week treatment with GS-5816 Healio Hepatology / 17 November 2014 Merck’s four-week treatment for hepatitis C misses the mark Wall Street Journal / 11 November 2014 View more > Other pages in this section Latest news All the news Conference news Email bulletin archive